|Articles|July 8, 2004

Early-stage prostate Ca is likely to become aggressive, lethal in long term

Even though most early-stage prostate cancers have a slow course, the cancers can become more aggressive and lethal in the long term, according to a study by Swedish researchers (JAMA 2004; 291:2713-9).

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Latest CME

Video

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | South Carolina

Scott T. Tagawa, MD, MS, FACP, FASCO; Anusha Madadi, MD

Video

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | West Virginia

Jeremie Calais, MD, PhD; Jason Zhu, MD

Video

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee

Nasfat Shehadeh, MD; Jeremie Calais, MD, PhD

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Register now!

Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Multimedia

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Multimedia

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Multimedia

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Early-stage prostate Ca is likely to become aggressive, lethal in long term

Newsletter

Related Content

Theranostic therapies expand frontline use in prostate cancer

BioProtect Balloon Spacer shows sustained quality-of-life benefits in long-term study

FDA removes warning labels on hormone replacement therapy

Urologist Elizabeth Mobley, MD, discusses advances in bladder and kidney cancer

Pearls & Perspectives: Innovation in Men’s Health, with Ryan Griggs, DO

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | South Carolina

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | West Virginia

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee

DSUI Urology on the Beach

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Radioligand Therapy 101: The Science Behind the Strategy

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Trending on Urology Times

Theranostic therapies expand frontline use in prostate cancer

FDA removes warning labels on hormone replacement therapy

BioProtect Balloon Spacer shows sustained quality-of-life benefits in long-term study

Jonathan Henderson, MD, outlines key lessons in urology practice management

Data support safe reinduction of nadofaragene firadenovec in NMIBC